Abstract
Background Helicobacter pylori is responsible for gastric cancer in approximately tens of millions of patients. Gastric cancer in Sudan represents one of the top causing death among cancers with about 686 cases per year and a 2.7 % mortality rate. IL-1RN VNTR polymorphism has been reported to increase the risk of gastric cancer.
Objective The purpose of this study was to assess the association of the 86 bp VNTR polymorphism of IL- 1RN gene and the susceptibility to H. pylori infection and gastric cancer in the Sudanese population.
Materials and methods Genomic DNA was extracted from 114 subjects. Of whom 60 had gastritis and duodenitis, 26 had a peptic ulcer, 16 had gastric cancer and 12 had normal gastroscopy findings. H. pylori infection was investigated by specific 16S rRNA. And IL-1RN VNTR polymorphism at intron 2 was genotyped using the PCR method and direct sequencing for random samples.
Results The positive H. pylori infection rate among participants was 47.37%. There is a lack of a significant difference in IL- 1RN genotype with H. pylori infection (p-value=1.0000). The IL-1 RN L/L genotype was significantly more frequent in a patient with benign disorders (gastritis or duodenitis or peptic ulcer), Odd=6.000 (95% CI =1.750-20.57, P=0.0056). While the heterozygote genotype 2/L was associated with an increased risk of gastric cancer with OR = 12.83 (95% CI = 1.261-130.6, P=0.0302).
Conclusion Independently carriage of IL-1RN *2 allele was associated with increased risk of gastric cancer in the Sudanese population. Notwithstanding the relatively small sample size of the study population, our findings show that the host genetic can be a useful tool for identifying high-risk individuals among dyspeptic patients; and also underscore the role played by host genetics in gastric carcinogenesis. To the best of our knowledge, this is the first study in Sudan concerning this issue.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data regarding IL-1RN genotypes and alleles distributions among participants that used to support the findings of this study are included within the supplementary information file.